{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:24:12Z","timestamp":1790792652309,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03267-8","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:02:35Z","timestamp":1723478555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice"],"prefix":"10.1007","volume":"316","author":[{"given":"Abbas F. Abdul","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-1329","authenticated-orcid":false,"given":"Nora","family":"Hosny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elrosasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Kobtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Ahmed","family":"Shafik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Raed","family":"Alnatsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Abo","family":"Zeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugahed","family":"Qarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yathrib K.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Abbas","family":"Al-Sultany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"3","key":"3267_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1346-8138.15743","volume":"48","author":"C Bergqvist","year":"2021","unstructured":"Bergqvist C, Ezzedine K (2021) Vitiligo: a focus on pathogenesis and its therapeutic implications. J Dermatol 48(3):252\u2013270","journal-title":"J Dermatol"},{"issue":"6","key":"3267_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology 236(6):571\u2013592","journal-title":"Dermatology"},{"key":"3267_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16883","volume-title":"Ocular findings in vitiligo and recommendations for dermatologists","author":"S Poondru","year":"2023","unstructured":"Poondru S, Alvi S, LeWitt TM, Haddadin R, Kundu RV (2023) Ocular findings in vitiligo and recommendations for dermatologists. Wiley Online Library, Hoboken"},{"issue":"1","key":"3267_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","volume":"158","author":"K Gandhi","year":"2022","unstructured":"Gandhi K, Ezzedine K, Anastassopoulos KP, Patel R, Sikirica V, Daniel SR et al (2022) Prevalence of vitiligo among adults in the United States. JAMA Dermatol 158(1):43\u201350","journal-title":"JAMA Dermatol"},{"key":"3267_CR5","doi-asserted-by":"crossref","unstructured":"RM Halder JL Chappell Eds 2009 Vitiligo update. Semin Cutan Med Surg. WB Saunders","DOI":"10.1016\/j.sder.2009.04.008"},{"issue":"1","key":"3267_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Group VW","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Group VW (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1\u201313","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3267_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","volume":"15","author":"G Iannella","year":"2016","unstructured":"Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A et al (2016) Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 15(4):335\u2013343","journal-title":"Autoimmun Rev"},{"key":"3267_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"ML Frisoli","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE (2020) Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621\u2013648","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3267_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG Van Den Boorn","year":"2009","unstructured":"Van Den Boorn JG, Konijnenberg D, Dellemijn TA, Van Der Veen JW, Bos JD, Melief CJ et al (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129(9):2220\u20132232","journal-title":"J Invest Dermatol"},{"issue":"223","key":"3267_CR10","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M-W et al (2014) CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med 6(223):223ra23-ra23","journal-title":"Sci Transl Med"},{"issue":"2","key":"3267_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG et al (2017) Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 137(2):350\u2013358","journal-title":"J Invest Dermatol"},{"issue":"3","key":"3267_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","volume":"79","author":"A-M Hosking","year":"2018","unstructured":"Hosking A-M, Juhasz M, Mesinkovska NA (2018) Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol 79(3):535\u2013544","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3267_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R et al (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370\u2013371","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3267_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y et al (2017) Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 76(6):1054\u201360.E1","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"3267_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","volume":"78","author":"D Joshipura","year":"2018","unstructured":"Joshipura D, Alomran A, Zancanaro P, Rosmarin D (2018) Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol 78(6):1205\u20137.E1","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3267_CR16","first-page":"29","volume":"2","author":"JJ Emer","year":"2009","unstructured":"Emer JJ, Claire W (2009) Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol 2(5):29","journal-title":"J Clin Aesthet Dermatol"},{"issue":"15","key":"3267_CR17","first-page":"3109","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood J Am Soc Hematol 115(15):3109\u20133117","journal-title":"Blood J Am Soc Hematol"},{"issue":"10244","key":"3267_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB et al (2020) Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. The Lancet 396(10244):110\u2013120","journal-title":"The Lancet"},{"key":"3267_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104499","volume":"81","author":"A Sheikh","year":"2022","unstructured":"Sheikh A, Rafique W, Owais R, Malik F, Ali E (2022) FDA approves Ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology. Ann Med Surg 81:104499","journal-title":"Ann Med Surg"},{"issue":"4","key":"3267_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DY et al (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863\u2013872","journal-title":"J Am Acad Dermatol"},{"key":"3267_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-62960-5","volume-title":"Vitiligo","author":"M Picardo","year":"2019","unstructured":"Picardo M, Ta\u00efeb A (2019) Vitiligo. Springer, Berlin"},{"key":"3267_CR22","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/ng.3680","volume":"48","author":"Y Jin","year":"2016","unstructured":"Jin Y, Andersen G, Yorgov D et al (2016) Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet 48:1418\u20131424","journal-title":"Nat Genet"},{"key":"3267_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","volume":"35","author":"N Elbuluk","year":"2017","unstructured":"Elbuluk N, Ezzedine K (2017) Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin 35:117\u2013128","journal-title":"Dermatol Clin"},{"key":"3267_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/exd.12112","volume":"22","author":"M Wagner","year":"2013","unstructured":"Wagner M, Trost A, Hintner H et al (2013) Imbalance of intermediate filament component keratin 14 contributes to increased stress signalling in epidermolysis bullosa simplex. Exp Dermatol 22:292\u2013294","journal-title":"Exp Dermatol"},{"key":"3267_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jcp.22027","volume":"223","author":"ML Dell'anna","year":"2010","unstructured":"Dell\u2019anna ML, Ottaviani M, Bellei B et al (2010) Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. J Cell Physiol 223:187\u2013193","journal-title":"J Cell Physiol"},{"key":"3267_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/jcp.22023","volume":"223","author":"M Norrby","year":"2010","unstructured":"Norrby M, T\u00e5gerud S (2010) Mitogen-activated protein kinase-activated protein kinase 2 (MK2) in skeletal muscle atrophy and hypertrophy. J Cell Physiol 223:194\u2013201","journal-title":"J Cell Physiol"},{"key":"3267_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I et al (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77:1\u201313","journal-title":"J Am Acad Dermatol"},{"key":"3267_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fendo.2018.00197","volume":"9","author":"M-I Kotb El-Sayed","year":"2018","unstructured":"Kotb El-Sayed M-I, Abd El-Ghany AA, Mohamed RR (2018) Neural and endocrinal pathobiochemistry of vitiligo: comparative study for a hypothesized mechanism. Front Endocrinol 9:197","journal-title":"Front Endocrinol"},{"key":"3267_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","volume":"35","author":"M Rashighi","year":"2017","unstructured":"Rashighi M, Harris JE (2017) Vitiligo pathogenesis and emerging treatments. Dermatol Clin 35:257\u2013265","journal-title":"Dermatol Clin"},{"key":"3267_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1346-8138.2010.01139.x","volume":"38","author":"R Yaghoobi","year":"2011","unstructured":"Yaghoobi R, Omidian M, Bagherani N (2011) Vitiligo: a review of the published work. J Dermatol 38:419\u2013431","journal-title":"J Dermatol"},{"key":"3267_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.det.2016.11.012","volume":"35","author":"PE Grimes","year":"2017","unstructured":"Grimes PE, Nashawati R (2017) The role of diet and supplements in vitiligo management. Dermatol Clin 35:235\u2013243","journal-title":"Dermatol Clin"},{"key":"3267_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10354-014-0288-7","volume":"164","author":"T Lotti","year":"2014","unstructured":"Lotti T, Zanardelli M, D\u2019erme AM (2014) Vitiligo: what\u2019s new in the psycho-neuro-endocrine-immune connection and related treatments. Wien Med Wochenschr 164:278\u2013285","journal-title":"Wien Med Wochenschr"},{"key":"3267_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/phpp.12277","volume":"33","author":"R Li","year":"2017","unstructured":"Li R, Qiao M, Wang X et al (2017) Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. Photodermatol Photoimmunol Photomed 33:22\u201331","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"3267_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.det.2016.11.009","volume":"35","author":"TF Mohammad","year":"2017","unstructured":"Mohammad TF, Hamzavi IH (2017) Surgical therapies for vitiligo. Dermatol Clin 35:193\u2013203","journal-title":"Dermatol Clin"},{"issue":"16","key":"3267_CR35","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K, TRuE-V Study Group (2022) Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. New Engl J Med 387(16):1445\u20131455. https:\/\/doi.org\/10.1056\/NEJMoa2118828","journal-title":"New Engl J Med"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03267-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03267-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03267-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:05:46Z","timestamp":1729699546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03267-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03267-8","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"518"}}